US District Court rules in favor of Lilly's Alimta patent
Eli Lilly and Co said a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India’s Dr. Reddy’s Laboratories from launching generics until the patent expires.
The patent for Lilly’s top-selling cancer drug will expire in May 2022.
“Lilly’s extensive research to discover the Alimta vitamin regimen patent deserves intellectual property protection,” Lilly’s senior vice president Michael Harrington said in a statement.
Lilly has faced several legal challenges to its right to avoid generic competition for Alimta, whose chemical name is pemetrexed.
(Reporting by Vibhuti Sharma in Bengaluru; Editing by Arun Koyyur)
Alimtacancer drugDr Reddy's LaboratoriesDr Reddys LabEli LillyFavorgeneric competitiongenericshospiraMichael HarringtonpatentrulesUS District Courtvitamin
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd